Show simple item record

dc.contributor.authorYu, Rui
dc.contributor.authorAlbarenque, Stella Maris
dc.contributor.authorCool, Robbert H
dc.contributor.authorQuax, Wim J
dc.contributor.authorMohr, Andrea
dc.contributor.authorZwacka, Ralf M
dc.date.accessioned2018-09-20T16:28:51Z
dc.date.available2018-09-20T16:28:51Z
dc.date.issued2014-11-20
dc.identifier.citationYu, Rui; Albarenque, Stella Maris; Cool, Robbert H; Quax, Wim J; Mohr, Andrea; Zwacka, Ralf M (2014). Dr4 specific trail variants are more efficacious than wild-type trail in pancreatic cancer. Cancer Biology & Therapy 15 (12), 1658-1666
dc.identifier.issn1538-4047,1555-8576
dc.identifier.urihttp://hdl.handle.net/10379/14496
dc.description.abstractCurrent treatment modalities for pancreatic carcinoma afford only modest survival benefits. TRAIL, as a potent and specific inducer of apoptosis in cancer cells, would be a promising new treatment option. However, since not all pancreatic cancer cells respond to TRAIL, further improvements and optimizations are still needed. One strategy to improve the effectiveness of TRAIL-based therapies is to specifically target one of the 2 cell death inducing TRAIL-receptors, TRAIL-R1 or TRAIL-R2 to overcome resistance. To this end, we designed constructs expressing soluble TRAIL (sTRAIL) variants that were rendered specific for either TRAIL-R1 or TRAIL-R2 by amino acid changes in the TRAIL ectodomain. When we expressed these constructs, including wild-type sTRAIL (sTRAIL(wt)), TRAIL-R1 (sTRAIL(DR4)) and TRAIL-R2 (sTRAIL(DR5)) specific variants, in 293 producer cells we found all to be readily expressed and secreted into the supernatant. These supernatants were subsequently transferred onto target cancer cells and apoptosis measured. We found that the TRAIL-R1 specific variant had higher apoptosis-inducing activity in human pancreatic carcinoma Colo357 cells as well as PancTu1 cells that were additionally sensitized by targeting of XIAP. Finally, we tested TRAIL-R1 specific recombinant TRAIL protein (rTRAIL(DR4)) on Colo357 xenografts in nude mice and found them to be more efficacious than rTRAIL(wt). Our results demonstrate the benefits of synthetic biological approaches and show that TRAIL-R1 specific variants can potentially enhance the therapeutic efficacy of TRAIL-based therapies in pancreatic cancer, suggesting that they can possibly become part of individualized and tumor specific combination treatments in the future.
dc.publisherInforma UK Limited
dc.relation.ispartofCancer Biology & Therapy
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Ireland
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/3.0/ie/
dc.subjectapoptosis
dc.subjectdr4 specific trail variant
dc.subjectpancreatic cancer
dc.subjecttrail
dc.subjecttrail receptor
dc.subjectxiap
dc.subjectreceptor-selective mutants
dc.subjectmesenchymal stem-cells
dc.subjectfactor-kappa-b
dc.subjectinduced apoptosis
dc.subjectcolorectal-cancer
dc.subjectcarcinoma cells
dc.subjectantitumor-activity
dc.subjectmonoclonal-antibody
dc.subjectdeath receptors
dc.subjectdecoy receptors
dc.titleDr4 specific trail variants are more efficacious than wild-type trail in pancreatic cancer
dc.typeArticle
dc.identifier.doi10.4161/15384047.2014.972183
dc.local.publishedsourcehttp://www.tandfonline.com/doi/pdf/10.4161/15384047.2014.972183?needAccess=true
nui.item.downloads0


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Ireland
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland